المصدر: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06203600Test

المؤلفون: Arcus Biosciences, Inc.

المصدر: A Phase 1b/2 Dose-finding and Expansion Study Evaluating the Safety and Efficacy of Zanzalintinib (XL092) Combined With Either AB521 or AB521 Plus Nivolumab in Subjects With Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors.

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06191796Test

المصدر: A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06188208Test

المؤلفون: Breast Cancer Research Foundation

المصدر: A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06179303Test

المصدر: Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06176989Test

Other URLs: https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_001552-C.htmlTest

المصدر: A Phase 3, Multi-Center, Double-Blind, Randomized, Efficacy and Safety Study of M108 Monoclonal Antibody Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06177041Test

المصدر: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06120283Test

المصدر: Phase I Clinical Trial to Evaluate the Safety and Tolerability of NEOG-100 in Patients With Advanced Breast Cancer and Lung Cancer

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06107894Test

المؤلفون: National Cancer Institute (NCI)

المصدر: Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06075524Test

Other URLs: https://www.mayo.edu/research/clinical-trialsTest

المصدر: A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06066138Test

Other URLs: https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_001559-C.htmlTest